FORM 5
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ] Form 3 Holdings Reported
[ X ] Form 4 Transactions Reported 		UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

                                                                                  

OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden
hours per response... 1.0
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Ruchefsky Steven B

2. Issuer Name and Ticker or Trading Symbol

Arno Therapeutics, Inc [ARNI]

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)

(Last)          (First)          (Middle)

ARNO THERAPEUTICS, INC.,  200 ROUTE 31 NORTH, SUITE 104

3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY)
12/31/2014 
(Street)

FLEMINGTON, NJ 08822

(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person


Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Amount (A) or (D) Price
Common Stock                 1596272   I   By Commercial Street Capital, LLC   (1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
(A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
2012 Series B Warrants (right to buy)   $2.40   10/28/2014     D4   (2)    520833    10/29/2013   10/31/2014   Common Stock   520833   $0   0   I   By Commercial Street Capital, LLC   (1)
2012 Series B Warrants (right to buy)   $2.40   10/28/2014     A4   (2) 520833       10/29/2013   1/31/2015   Common Stock   520833   $0   520833   I   By Commercial Street Capital, LLC   (1)
2013 Series E Warrants (right to buy)   $2.40   10/28/2014     D4   (2)    687500    10/29/2013   12/31/2014   Common Stock   687500   $0   0   I   By Commercial Street Capital, LLC   (1)
2013 Series E Warrants (right to buy)   $2.40   10/28/2014     A4   (2) 687500       10/29/2013   1/31/2015   Common Stock   687500   $0   687500   I   By Commercial Street Capital, LLC   (1)

Explanation of Responses:
( 1)  The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
( 2)  The reported transaction resulted from the Issuer's unilateral extension of the expiration date of the outstanding warrant from 10/31/14 to 1/31/15. Such extension resulted in the deemed cancellation of the "originally" issued old warrant and the issuance of a replacement warrant. The Series E warrant was originally granted on 10/29/13.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Ruchefsky Steven B
ARNO THERAPEUTICS, INC.
200 ROUTE 31 NORTH, SUITE 104
FLEMINGTON, NJ 08822 		X



Signatures
Christopher J. Melsha as Attorney-in-Fact for Steven B. Ruchefsky pursuant to Power of Attorney previously filed. 2/17/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Grafico Azioni Arno Therapeutics (CE) (USOTC:ARNI)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Arno Therapeutics (CE)
Grafico Azioni Arno Therapeutics (CE) (USOTC:ARNI)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Arno Therapeutics (CE)